Multiple Sclerosis (MS) is a chronic, debilitating disease affecting the central nervous system, leading to progressive disability. Most MS patients initially experience a relapsing-remitting (RR) phase, with episodes of neurological symptoms.

However, a significant portion eventually transition to secondary progressive MS (SPMS), where disability accumulates. Current treatments target the adaptive immune system and are effective during the RR phase but fail to stop the progression in SPMS, highlighting a significant unmet medical need.

Our project aims to develop a small molecule preclinical drug candidate for the treatment of progressive multiple sclerosis. Our approach is unique because it targets a signaling pathway discovered recently to be involved in the inflammatory process during autoimmunity directed toward myelin.